Solvonis Therapeutics CEO on name change, Awakn acquisition and 2025 priorities

Proactive - Interviews for investors

Solvonis Therapeutics CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's rebranding from Graft Polymer (UK) PLC (LSE:GPL) to Solvonis Therapeutics PLC, reflecting its commitment to advancing mental health and substance use disorder treatments. Tennyson highlighted Solvonis' plans to acquire Awakn Life Sciences in an all-stock deal, emphasising Awakn’s promising data, experienced team, and valuation. Awakn’s lead program targeting severe alcohol use disorder has entered Phase 3 trials with UK government funding, an achievement Tennyson described as “unheard of for a Phase 3 trial in this indication.” The program showed a 50% reduction in heavy drinking days and a remarkable 86% abstinence rate over six months post-treatment. or 2025, Solvonis aims to complete the acquisition efficiently, progress Awakn’s lead program, and advance a secondary program targeting alcohol use disorder in the US. Tennyson stated, “We’re very happy with what 2025 will hold for the company and our shareholders.” Stay tuned for more updates on Solvonis Therapeutics' innovative work in mental health. Visit Proactive's YouTube channel for more interviews, and don't forget to like, subscribe, and enable notifications for future updates. #SolvonisTherapeutics #MentalHealth #AlcoholUseDisorder #BiotechInnovation #AwaknLifeSciences #ClinicalTrials #SubstanceUseDisorders #Neuropsychology #HealthcareAdvances #InvestorUpdates#ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews